Tags

Type your tag names separated by a space and hit enter

Octreotide: a therapeutic option for idiopathic intracranial hypertension.

Abstract

PURPOSE

To study the effects of octreotide, a somatostatin analogue, in patients with Idiopathic Intracranial Hypertension (IIH).

METHODS

We performed a prospective, open-label study of the effect of Octreotide on 26 patients with symptoms and signs of IIH, investigated by brain MRI and lumbar puncture. Octreotide was administered subcutaneously, at an initial dose of 0.3 mg/day; and was gradually increased until headache was relieved (upper-dose limit: 1 mg/day). Treatment with octreotide at 1 mg/day was administered for a maximum of six to eight months and afterwards the dose was gradually tapered. Patients were followed prospectively every month for three years. CSF opening pressure was measured before the treatment was started and again in the first follow-up examination, on month one. In all follow-up visits the presence of papilledema was evaluated by fundoscopy; visual fields and visual acuity were also examined.

RESULTS

Overall 24/26 patients improved significantly (92%). Headache was relieved within days (1-10, median 7 days). Papilledema subsided in all 24 patients, in up to two months (35 to 68, median 45 days). Visual disturbances, initially presenting in 20 of our patients, improved in 18 (90%). The mean reduction in CSF pressure after treatment was 20.72A+/-10.7 cmH2O (range 2 to 48). Patients were followed for three years after cessation of treatment. No recurrence of papilledema, or any other symptoms, has been observed.

CONCLUSIONS

Octreotide resulted in a significant and sustained improvement of IIH in our patients. These results suggest that it may be an effective alternative to existing treatments for IIH.

Authors+Show Affiliations

Department of Neurology, Athens General Hospital G Gennimatas, Athens, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

17700925

Citation

Panagopoulos, G N., et al. "Octreotide: a Therapeutic Option for Idiopathic Intracranial Hypertension." Neurology, Neurophysiology, and Neuroscience, 2007, p. 1.
Panagopoulos GN, Deftereos SN, Tagaris GA, et al. Octreotide: a therapeutic option for idiopathic intracranial hypertension. Neurol Neurophysiol Neurosci. 2007.
Panagopoulos, G. N., Deftereos, S. N., Tagaris, G. A., Gryllia, M., Kounadi, T., Karamani, O., ... Piadites, G. (2007). Octreotide: a therapeutic option for idiopathic intracranial hypertension. Neurology, Neurophysiology, and Neuroscience, p. 1.
Panagopoulos GN, et al. Octreotide: a Therapeutic Option for Idiopathic Intracranial Hypertension. Neurol Neurophysiol Neurosci. 2007 Jul 10;1. PubMed PMID: 17700925.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Octreotide: a therapeutic option for idiopathic intracranial hypertension. AU - Panagopoulos,G N, AU - Deftereos,S N, AU - Tagaris,G A, AU - Gryllia,M, AU - Kounadi,T, AU - Karamani,O, AU - Panagiotidis,D, AU - Koutiola-Pappa,E, AU - Karageorgiou,C E, AU - Piadites,G, Y1 - 2007/07/10/ PY - 2007/05/28/received PY - 2007/07/06/accepted PY - 2007/8/19/pubmed PY - 2008/2/21/medline PY - 2007/8/19/entrez SP - 1 EP - 1 JF - Neurology, neurophysiology, and neuroscience JO - Neurol Neurophysiol Neurosci N2 - PURPOSE: To study the effects of octreotide, a somatostatin analogue, in patients with Idiopathic Intracranial Hypertension (IIH). METHODS: We performed a prospective, open-label study of the effect of Octreotide on 26 patients with symptoms and signs of IIH, investigated by brain MRI and lumbar puncture. Octreotide was administered subcutaneously, at an initial dose of 0.3 mg/day; and was gradually increased until headache was relieved (upper-dose limit: 1 mg/day). Treatment with octreotide at 1 mg/day was administered for a maximum of six to eight months and afterwards the dose was gradually tapered. Patients were followed prospectively every month for three years. CSF opening pressure was measured before the treatment was started and again in the first follow-up examination, on month one. In all follow-up visits the presence of papilledema was evaluated by fundoscopy; visual fields and visual acuity were also examined. RESULTS: Overall 24/26 patients improved significantly (92%). Headache was relieved within days (1-10, median 7 days). Papilledema subsided in all 24 patients, in up to two months (35 to 68, median 45 days). Visual disturbances, initially presenting in 20 of our patients, improved in 18 (90%). The mean reduction in CSF pressure after treatment was 20.72A+/-10.7 cmH2O (range 2 to 48). Patients were followed for three years after cessation of treatment. No recurrence of papilledema, or any other symptoms, has been observed. CONCLUSIONS: Octreotide resulted in a significant and sustained improvement of IIH in our patients. These results suggest that it may be an effective alternative to existing treatments for IIH. SN - 1933-1266 UR - https://www.unboundmedicine.com/medline/citation/17700925/Octreotide:_a_therapeutic_option_for_idiopathic_intracranial_hypertension L2 - http://www.diseaseinfosearch.org/result/9667 DB - PRIME DP - Unbound Medicine ER -